[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.197.114. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
April 1, 1998

Malaria Prevention for Travelers

Author Affiliations
 

Margaret A.WinkerMD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Senior EditorIndividualAuthor

JAMA. 1998;279(13):990-991. doi:10-1001/pubs.JAMA-ISSN-0098-7484-279-13-jbk0401

To the Editor.—Mefloquine (250 mg every 7 days) is the current drug regimen recommended by the World Health Organization1 and the Centers for Disease Control and Prevention2 for prevention of malaria in East Africa. As indicated in the article by Drs Lobel and Kozarsky,3 mefloquine treatment failure is well documented in Thailand and Cameroon. In Africa, failure of mefloquine prophylaxis despite adequate drug concentration has been documented in only 4 West African countries4 and in Somalia.5 We report a case of mefloquine prophylaxis failure in a malaria naive resident of Kenya.

First Page Preview View Large
First page PDF preview
First page PDF preview
×